CNSP

CNS Pharmaceuticals, Inc. [CNSP] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CNSP Stock Summary

Top 10 Correlated Stocks

CNSP

In the News

CNSP Financial details

Company Rating
-
Market Cap
2.59M
Income
-18.86M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.25
Forward P/E
-
PEG
0.05
P/S
-
P/B
-2.76
P/C
-
P/FCF
-0.51
Quick Ratio
0.22
Current Ratio
0.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.66
EPS next Y
-
EPS next Q
-
EPS this Y
-55.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-12.04%
-
-
-
-
SMA20
-10.52%
SMA50
-35.95%
SMA100
-17.93%
Inst Own
-
Inst Trans
-
ROA
-816%
ROE
-616%
ROC
10.91%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.22-4.4
52W High
-
52W Low
-
RSI
30.33
Rel Volume
0.04
Avg Volume
443.89K
Volume
16.42K
Perf Week
-19.35%
Perf Month
-21.64%
Perf Quarter
-50%
Perf Half Y
-48.58%
-
-
-
-
Beta
1.088
-
-
Volatility
0.48%, 0.59%
Prev Close
-3.85%
Price
5.25
Change
-6.08%

Something similar

Top by Market Cap
FB2A.DE
JPM
VOO
MSFT
APC.DE
Same Sector
SPARC.NS
0H8I.L
EXE.TO
CRBP
200028.SZ
Top Correlated Stocks
NPSKY
8391.HK
BIRD.L
0103.HK
WOR
Similar Market Cap
NAVB
VS
I7N.DE
CBX.L
IVX.V

Company Profile

Healthcare Biotechnology
  • Volume Average 443.89K
  • Market Capitalization 2.59M
  • Employee 3
  • CEO Mr. John Michael Climaco Esq., J.D.
  • Headquarters Houston,TX,US
  • IPO Date 2019-11-08
  • Website https://www.cnspharma.com

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.